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The 26S proteasome is a protease complex that completely degrades substrate proteins marked with a chain of ubiquitins, but is also able to perform endoproteolytic cleavage. A new study now demonstrates that regulated ubiquitin-proteasome-dependent processing ameliorates proteasomal inhibition.
Thorsten Hoppe
The proteasome is essential for ubiquitin-mediated degradation of damaged or regulatory proteins [1] . Its 20S core particle is a cylinder formed by four seven-subunit rings that contains the proteolytic sites. The unfolding and translocation of ubiquitylated substrates into the hollow 20S particle is catalyzed by two 19S cap structures, one sitting over each end of the cylinder [2] . This 'self-compartmentalized' architecture of the 26S proteasome ensures the highly selective nature of the ubiquitin-proteasome system; only ubiquitylated proteins are allowed to reach the active sites within the inner 20S core and get completely cleaved into small peptides [3] . It has been shown recently that the proteasome does not always fully degrade substrate proteins, with endoproteolytic cleavage by the proteasome sometimes initiating processing of dormant precursor proteins. These processing events might arise from internal cleavage of polypeptide loops that enter the 20S core particle of the proteasome [4] . Such an endoproteolytic cut could be a general mechanism for proteasomal degradation, since substrate turnover is often associated with the appearance of cleavage products [5] . These by-products are usually degraded with a different half-life compared with the particular full-length proteins. However, the specific topology of protein domains and/or protective binding partners can prevent proteasomal degradation of certain biologically active protein fragments.
Examples of substrates of this regulatory proteasomal cleavage mechanism -termed regulated ubiquitin-proteasome-dependent processing (RUP) -are the transcription factors NF-kB, Spt23p and Mga2p [6, 7] . NF-kB governs immune and inflammatory responses linked to apoptosis and cancer. Ubiquitylation of its inactive precursor, p105, results in proteasomal degradation of the carboxy-terminal region and release of the stable p50 subunit of NF-kB [6] . Spt23p and Mga2p are distant NF-kB homologues that control fatty acid metabolism in the budding yeast Saccharomyces cerevisiae. Similar to NF-kB, both are produced as dormant precursors (p120) but are anchored to the endoplasmic reticulum (ER). Intriguingly, processing of the p120 forms depends on the composition of the ER membrane and liberates the active amino-terminal transcription factor domain p90 when unsaturated fatty acids are needed [7] .
These data provide evidence that both conformational and functional properties of the precursor proteins influence the efficiency of RUP. Conversely, little is known about the impact of the proteasome in the coordination of this unconventional cleavage process with physiological demands. A new study by the Goldberg laboratory, published in a recent issue of Current Biology, now highlights a fascinating role of RUP that links processing of the transcription factor Nrf1 to proteasomal activity and vice versa [8] .
In this new work, the authors addressed the previously reported, counterintuitive observation that pharmacological inhibition of the 26S proteasome often results in enhanced proteasomal activity [9] . Aside from its use as a tool to reveal cellular functions, the proteasomal inhibitor bortezomib (BTZ) is successfully used in the treatment of multiple myeloma, a cancer of antibody-generating plasma cells [10] . However, increased expression of 26S subunits in response to BTZ treatment provides a compensatory response mechanism that often supports drug resistance and survival of cancer cells. To unravel this problem, Sha and Goldberg [8] focused on the central role of the transcription factor Nrf1, which is known to bind many promoters of 26S proteasomal genes [11, 12] . In contrast to its homolog Nrf2, Nrf1 induces the expression of all 26S subunits upon treatment with the proteasome inhibitors BTZ, MG132, MG262, or epoxomicin [12] . Conversely, cancer cells lacking Nrf1 are less resistant against proteasomal inhibition, suggesting a key role for Nrf1 in the paradoxical upregulation of proteasome activity in response to drug-mediated proteasomal inhibition.
In this context it is interesting to note that Nrf1 protein levels are regulated by ubiquitin-mediated degradation dependent on the E3 ubiquitin ligase enzymes Hrd1, Fbw7, and b-TRCP [12] [13] [14] . Thus, increased proteasomal gene transcription caused by drug treatment could be explained by stabilization of the Nrf1 protein.
However, this simplified model is not compatible with several findings. First, Nrf2 is similarly regulated by the ubiquitin-proteasome system but has not been implicated in proteasomal drug resistance [15] . Second, the new study by Sha and Goldberg [8] shows that high concentrations of proteasomal inhibitors block the induction of 26S subunits in contrast to low concentrations. Third, Nrf1 is attached to the ER membrane and release of the transcription factor requires proteolytic processing [16] .
To pin down the concentrationdependent nature of proteasomal inhibition, Goldberg and colleagues [8] suggested that RUP could be a candidate mechanism responsible for Nrf1 activation. Indeed, they convincingly showed proteasome-dependent cleavage of the membrane-bound p85 Nrf1 precursor into the active p75 form. Intriguingly, Nrf1 processing only occurred when the 26S proteasome was partially active, and this processing was blocked upon complete proteasomal inhibition. This correlation between proteasomal activity and Nrf1 activation provides a clear explanation for how drug treatment might result in increased 26S gene expression. In contrast to complete degradation of ubiquitylated Nrf1, partially inhibited 26S proteasomes with limited proteolytic activity are inefficient in complete Nrf1 turnover and instead release the cleaved Nrf1 p75 fragment, which activates transcription in the nucleus. A subsequent increase in proteasomal capacity might terminate the upregulation of 26S subunits by degradation of the active p75 form of Nrf1 (Figure 1 ). This elegant response mechanism allows cancer cells to survive drug treatment by increasing the amount of active 26S proteasomes.
In regard to cancer therapy, this exciting study reveals a new twist for the pharmacological treatment of multiple myeloma. As shown here, the efficiency of proteasomal inhibition can be monitored using Nrf1 processing as a biomarker, which might help in optimizing case-specific medication protocols. In contrast to cancer treatment, certain diseases and physiological conditions would benefit from an improved performance of the 26S proteasome. For example, overexpression of the 19S cap subunit RPN-6/PSMD11 results in enhanced stress resistance and longevity both in Caenorhabditis elegans and embryonic stem cells [17] . Further knowledge of the regulation of Nrf1 processing would provide new ways to antagonize the age-related decline in proteasomal capacity that is often associated with neurodegenerative diseases [18] . Given the current view of how proteasomal impairment contributes to the aging process, it would be The 85 kDa (p85) inactive Nrf1 precursor (red) is inserted into the ER with the carboxy-terminal domain facing the cytosol. At high levels of fully functional 26S proteasomes (dark grey), ubiquitylated p85 is completely degraded into small peptides (red balls) (1). In contrast, reduced proteolytic capacity of the 26S proteasome (light grey) caused by drug treatment or unfavorable physiological conditions instigates an endoproteolytic cleavage of Nrf1 and release of the 75 kDa (p75) fragment (2) . The active p75 form of the transcription factor then migrates into the nucleus and activates the transcription of 26S proteasomal genes and the ubiquitin-selective chaperone p97. This feedback response mechanism results in enhanced amounts of active proteasomes, which support complete degradation of Nrf1 (1) and consequently terminates RUP (2) . The ubiquitylation of Nrf1 is mediated by the E3 enzymes Hrd1, Fbw7, and b-TRCP, although regulatory inputs are not yet known. p97 might be involved in the mobilization process that liberates the p75 fragment from the ER membrane.
interesting to learn more about the physiological role of Nrf1 processing and the regulation of RUP under tissue-specific and stress-related conditions. The activation of Nrf1 is reminiscent of Spt23p processing in yeast, which also involves the ubiquitin-selective chaperone Cdc48p/p97 [19, 20] . Mechanistically, however, it expands the role of RUP by showing that it also acts as a feedback circuit that provides intensive crosstalk between the proteasome and its substrate. Given the growing list of identified substrates, proteasomal cleavage by RUP might be more common than initially expected and could lead to additional surprises.
As genomes evolve, proteins with novel functions arise primarily from gene duplication and divergence events. A new study identifies several molecular mechanisms by which related transcription factors diverge over time to control new sets of target genes and novel cellular functions. [1] shows how a family of duplicated transcription factors has diverged to play multiple roles in the biology of the yeast Candida albicans.
When a transcription factorencoding gene undergoes a complete duplication event, the two resultant identical copies will not be maintained in the genome for long unless they diverge such that each sister gene has at least one non-redundant function. This can occur by subfunctionalization, as in the case of the gene encoding the vertebrate transcription factor Engrailed-1. This gene exists in two copies in the zebrafish genome, each performing a subset of the functions of the ancestral engrailed-1 gene [2] ; a similar story has ben reported for two fish paralogs of pax6 [3] . Another type of divergence, known as
